Double-Blinded Drug Discovery® (DBD2)
The 99% failure rate in modern pharmaceutical R&D demands an overhaul of the present model; everyone agrees. Stakeholders (patients, taxpayers, and legislators) are losing patience - and life - waiting for applied research to deliver effective new medicines. Applying deeper knowledge of the chemical biology of drug action is the missing link crucial for translating bench-top discoveries into cures.
What Does DBD2 Provide?
LCGC provides university 'drug hunters' the best diversity and target-focused 'snapshots' from the millions of compounds owned by pharmas, pre-formatted on HTS-ready plates. We help optimize the assay parameters for successful application of the orthogonal-pooled screening (OPS) approach, which is one of LCGC's core technologies. Support extends to a point when the most potent and selective drug leads are in hand. The new drug leads discovered become a compelling basis for further collaboration between the institution and pharmaceutical company. Ultimately, this will enable deeper investigation into mechanisms of drug action and propel candidates more successfully to the clinic.
Image: Terra-cotta bas relief allegory of 'Industry and Invention' by Caspar Buberl
Brochures & Info Sheets